Published on December 17, 2009 at 4:07 AM
Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical
group, today announced that its partner Roche has disclosed headline
results of the fourth and fifth of eight T-emerge phase III studies in
patients with
diabetes for taspoglutide, the first once weekly
glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.
Taspoglutide originating from Ipsen’s research is developed by Roche.
T-emerge 5 (subcutaneous weekly taspoglutide versus daily
insulin
glargine as add-on to
metformin in patients failing on metformin and
sulfonylurea) and T-emerge 7 (subcutaneous weekly taspoglutide versus
placebo as add-on to metformin in patients with high BMI) both met their
respective primary endpoints of change in HbA1c. In both studies
taspoglutide was generally well tolerated. The most frequently reported
adverse events among taspoglutide treated patients were
nausea and
vomiting.
This compound is similar to the natural hormone GLP-1 which has a key
role in blood sugar regulation. GLP-1 analogues, which stimulate insulin
secretion and suppress glucagon secretion, are true innovations in the
diabetes field.
Source Ipsen
380b1d8a-9923-4edb-b050-6982e95a32a6|1|2.0
Posted in: Drug Trial News | Medical Condition News
Tags: Blindness, Blood Sugar, Diabetes, Diabetes Mellitus, Endocrinology, Exenatide, Hormone, Insulin, Insulin Glargine, Lantus, Life Expectancy, Metformin, Nausea, Neurology, Neuropathy, Oncology, Pioglitazone, Placebo, Renal Failure, Stroke, Sulfonylurea, Type 2 Diabetes, Vomiting